Alnylam Pharmaceuticals Inc (ALNY) Stock Analysis
Verdict: HOLD
Transition to sustained profitability and commercial RNAi growth supports fundamental upside despite recent technical weakness.
Investment score: 61/100
Analysis as of
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Alnylam Pharmaceuticals Inc opportunities and risks
What speaks for ALNY
- Commercial Inflection to Sustained Profitability
What speaks against ALNY
- Clinical and Regulatory Execution Hurdles
Frequently asked questions about Alnylam Pharmaceuticals Inc (ALNY)
Is ALNY stock a good investment?
The TradeMates model rates Alnylam Pharmaceuticals Inc as HOLD with an investment score of 61/100. Transition to sustained profitability and commercial RNAi growth supports fundamental upside despite recent technical weakness. This is algorithmic model output, not personal investment advice.
Is ALNY stock a buy?
The TradeMates model verdict for ALNY is HOLD with an investment score of 61/100. Treat this as a model signal to review, not a personal buy recommendation.